Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP19986 in Symptomatic GERD
NCT00557401Phase 2Completed
- Sponsor
- XenoPort, Inc.
- Start
- Nov 2007
- Primary completion
- Sep 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arbaclofen placarbil in gastroesophageal reflux disease (GERD), sponsored by XenoPort, Inc.. Started Nov 2007; status: completed.
02
Drugs
arbaclofen placarbil
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00557401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557401.